Skip to main content

Lisata Therapeutics, Inc.

LSTA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000320017

No open-market purchases or sales by Lisata Therapeutics, Inc. insiders were filed in the last 90 days; 38 institutions reported holding it in 13F filings for Q3 2026, worth $7.55M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$9.71M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +7 vs. previous quarter
38
13F valueReported value at the end of Q3 2026
$7.55M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$170.0K
−83.0% year over year
Net income, FY2025
-$16.6M
No comparable prior period
Free cash flow, FY2025
-$16.0M
No comparable prior period
Revenue, Q3 FY2026
$0
No comparable prior period

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $16.6M (9756.5% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
34.2K
Shares sold short
Change
+5.37K
+18.6% vs. previous
Days to cover
1.00
At average daily volume

Superinvestors holding LSTA, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding LSTA at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Lisata Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 10, 2021 (view filing)Dec 82 daysMyers Steven SDirectorPPurchase+33.8K$0.89+$30.1K+29.9%146.8K after

Top 10 13F holders, Q3 2026

See all 38 holders

The largest institutional positions in Lisata Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding LSTA in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Adage Capital Partners GP, L.L.C.2,487,646$3.58M0.01%+2,487,646New
TRV GP V, LLC455,192$655.5K0.14%+455,192New
Seven Fleet Capital Management LP371,411$534.8K0.10%+371,411New
FCPM III Services B.V.297,478$428.4K0.04%+297,478New
Vanguard Capital Management LLC278,837$401.5K0.00%00.0%Unchanged
Falcon Edge Capital, LP183,323$264.0K0.01%+183,323New
Sofinnova Investments, Inc.156,460$225.3K0.01%+156,460New
venBio Partners LLC156,460$225.3K0.05%+156,460New
Yakira Capital Management, Inc.135,520$195.1K0.05%−3,041−2.2%Reduced
Nantahala Capital Management, LLC101,221$145.8K0.01%+101,221New

Holders of 5% or more of LSTA

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Lisata Therapeutics, Inc..

Largest holders of LSTA from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Branham Justin Earl13G5.10%462.1K sharesNewAug 26, 20261 filingAug 26, 2026SEC